Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 14/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | PPID | Q08752 | 2/20 | 0.43 |
| ▸ | PPIB | P23284 | 1/20 | 0.43 |
| ▸ | PPIA | P62937 | 1/20 | 0.43 |
| ▸ | PPIG | Q13427 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 10/20 | 0.43 |
| ▸ | PPARD | Q03181 | 8/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1856323 | 0.89 | PPARA (0.49) | PPARALMNACYP1A2CYP3A4MAOA | |
| SCHEMBL13649255 | 0.89 | PPARA (0.49) | PPARALMNACYP1A2CYP3A4MAOA | |
| SCHEMBL4075927 | 0.89 | PPARA (0.49) | PPARALMNACYP1A2CYP3A4MAOA | |
| SCHEMBL3535230 | 0.86 | ESR1 (0.58) | PPARAPPARGPPARDESR1ESR2 | |
| SCHEMBL3535227 | 0.86 | ESR1 (0.58) | PPARAPPARGPPARDESR1ESR2 | |
| SCHEMBL16451001 | 0.85 | ESR1 (0.45) | PPARALMNACYP1A2CYP3A4MAOA | |
| SCHEMBL3536105 | 0.84 | PPARA (0.48) | PPARAPPARGPPARDESR1ESR2 | |
| SCHEMBL1750767 | 0.84 | PPARA (0.51) | PPARAPPARGPPARDESR1ESR2 | |
| SCHEMBL1750768 | 0.84 | PPARA (0.51) | PPARAPPARGPPARDESR1ESR2 | |
| SCHEMBL4074678 | 0.84 | PPARA (0.66) | PPARAPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105748-A1 | Novel beta-phenyl-alpha-oxysubstituted propionic derivatives: process for its preparation and their use in the preparation of pharmaceutically important compounds | REDDY'S LABORATORIES INC. | 2011-05-05 | — | — | US | claimed |
| EP-1436247-A1 | NOVEL-BETA-PHENYL-ALPHA-OXYSUBSTITUTED PROPIONIC DERIVATIVES: PROCESS FOR ITS PREPARATION AND THEIR USE IN THE PREPARATION OF PHARMACEUTICALLY IMPORTANT COMPOUNDS | Dr. Reddy's Laboratories Ltd. (IN) | 2004-07-14 | — | — | EP | claimed |
| WO-2003033456-A1 | NOVEL β-PHENYL-α-OXYSUBSTITUTED PROPIONIC DERIVATIVES: PROCESS FOR ITS PREPARATION AND THEIR USE IN THE PREPARATION OF PHARMACEUTICALLY IMPORTANT COMPOUNDS | DR. REDDY'S LABORATORIES LTD. (IN) | 2003-04-24 | — | — | WO | claimed |
| US-20110105748-A1 | Novel beta-phenyl-alpha-oxysubstituted propionic derivatives: process for its preparation and their use in the preparation of pharmaceutically important compounds | REDDY'S LABORATORIES INC. | 2011-05-05 | — | — | US | disclosed |
| US-20110105748-A1 | Novel beta-phenyl-alpha-oxysubstituted propionic derivatives: process for its preparation and their use in the preparation of pharmaceutically important compounds | REDDY'S LABORATORIES INC. | 2011-05-05 | — | — | US | disclosed |
| US-7598293-B2 | Compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598293-B2 | Compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-7579295-B2 | Catalytic hydrogenation processes | FIRMENICH SA (CH) | 2009-08-25 | — | — | US | disclosed |
| EP-1366004-B1 | CATALYTIC HYDROGENATION PROCESSES | FIRMENICH & CIE (CH) | 2008-05-14 | — | — | EP | disclosed |
| US-7365064-B2 | Benzoxazine and benzothiazine derivatives and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-04-29 | — | — | US | disclosed |
| US-7365064-B2 | Benzoxazine and benzothiazine derivatives and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-04-29 | — | — | US | disclosed |
| EP-1436268-A1 | BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dr. Reddy's Laboratories Ltd. (IN) | 2004-07-14 | — | — | EP | disclosed |
| EP-1436247-A1 | NOVEL-BETA-PHENYL-ALPHA-OXYSUBSTITUTED PROPIONIC DERIVATIVES: PROCESS FOR ITS PREPARATION AND THEIR USE IN THE PREPARATION OF PHARMACEUTICALLY IMPORTANT COMPOUNDS | Dr. Reddy's Laboratories Ltd. (IN) | 2004-07-14 | — | — | EP | disclosed |
| US-20040063966-A1 | Catalytic hydrogenation processes | RAUTENSTRAUCH VALENTIN (FR) | 2004-04-01 | — | — | US | disclosed |
| US-20030229083-A1 | Compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LIMITED | 2003-12-11 | — | — | US | disclosed |
| EP-1366004-A2 | CATALYTIC HYDROGENATION PROCESSES | Firmenich S.A. (CH) | 2003-12-03 | — | — | EP | disclosed |
| WO-2003048116-A2 | ESTERS AND AMIDES AS PPAR-ALPHA AGONISTS ____________ | DR. REDDY'S LABORATORIES LTD. (IN) | 2003-06-12 | — | — | WO | disclosed |
| WO-2003033481-A1 | BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND PARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S LABORATORIES LTD. (IN) | 2003-04-24 | — | — | WO | disclosed |
| WO-2003033456-A1 | NOVEL β-PHENYL-α-OXYSUBSTITUTED PROPIONIC DERIVATIVES: PROCESS FOR ITS PREPARATION AND THEIR USE IN THE PREPARATION OF PHARMACEUTICALLY IMPORTANT COMPOUNDS | DR. REDDY'S LABORATORIES LTD. (IN) | 2003-04-24 | — | — | WO | disclosed |
| WO-2002022526-A2 | CATALYTIC HYDROGENATION PROCESSES | FIRMENICH S.A. (CH) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105748-A1 | Novel beta-phenyl-alpha-oxysubstituted propionic derivatives: process for its preparation and their use in the preparation of pharmaceutically important compounds | PCCA, ADRA1B, ADRA2B | PPARA 822/4885LMNA 2490/4885CYP1A2 46/4885 |
| US-20030229083-A1 | Compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them | GPR119, LIPA, PCSK9 | PPARA 182/4885LMNA 841/4885CYP1A2 289/4885 |
| US-20040063966-A1 | Catalytic hydrogenation processes | HAO2, PYM1, MLX | PPARA 4135/4885LMNA 1946/4885CYP1A2 776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.